about
Molecular reclassification of Crohn's disease by cluster analysis of genetic variantsNew serological markers in inflammatory bowel disease are associated with complicated disease behaviourNatalizumab Induction and Maintenance Therapy for Crohn's DiseaseGenome-wide association defines more than 30 distinct susceptibility loci for Crohn's diseaseCommon variants at five new loci associated with early-onset inflammatory bowel diseaseGenome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility lociNatalizumab for active Crohn's diseaseMaintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe value of serologic markers in indeterminate colitis: a prospective follow-up studyCertolizumab pegol for the treatment of Crohn's diseasePharmacogenetics in inflammatory bowel diseaseInfliximab maintenance therapy for fistulizing Crohn's diseaseFontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose studyProgressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's diseaseA randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's diseasePostoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trialInfliximab for induction and maintenance therapy for ulcerative colitisHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trialResequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel diseaseNovel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL).Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseUnique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's diseaseMucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD.Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice.Immunosuppressive activity of a new pteridine derivative (4AZA1378) alleviates severity of TNBS-induced colitis in mice.Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's diseaseTolerance of arabinoxylan-oligosaccharides and their prebiotic activity in healthy subjects: a randomised, placebo-controlled cross-over study.Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis.Seroreactivity against glycolytic enzymes in inflammatory bowel disease.Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: a systematic reviewAssessment of the microbiota in microdissected tissues of Crohn's disease patientsAnti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.Association of a functional variant in the Wnt co-receptor LRP6 with early onset ileal Crohn's diseaseFecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
P50
Q21562166-9DA77958-0227-4E4A-AB45-FAA500D80828Q22242048-1FF25945-88FE-40A9-BC97-B8DFD102EAB7Q22250890-A757B95C-C2E4-4139-830B-C217463C9EE0Q22251069-1A1F264F-345D-4D95-BFF8-75978BD7ECB0Q24600801-793ADE61-0A1D-49A3-8AF8-8A40455B19B4Q24618592-6FC32506-2EB2-4F52-B118-9308336D597CQ28201431-5C5E7FC7-98B1-4916-9C59-EA16AB75797EQ28202504-ABDB34D7-FA61-44D3-AB0A-44C76461185AQ28216203-033E1439-DA90-48E8-89E2-E813279B7CE9Q28236746-B56A93E2-3CEA-4AE6-8D21-1553A9E149F0Q28246002-BA3B47DC-4D8B-4E9A-BFC2-1FE13E4EFEB6Q28246982-CA4A0F76-0303-4F4F-B183-423B97D9BD95Q28253174-205BCE8E-297F-46F9-8585-86452B8EB6FAQ28255557-84FE7C51-A2EF-47E0-90E1-4CD666533B52Q28270722-8A738CA7-3473-4BD1-B586-16556F2EE982Q28281664-4F1E0991-4962-4044-8AA5-27DED06DAD2BQ28285876-282C7497-1B2D-4B00-8098-8E11A5E9115CQ28296771-405F204C-2D14-4D71-955A-EED6DB2B8DD0Q28300680-F5A0AA55-4616-4734-A33D-F35FA4DD8AB2Q28469186-4635A272-156A-4663-BEE5-C5C6770632FFQ28943305-3B3CB6A0-327F-428A-ACC8-CE578137B2C0Q28943462-7B3525B0-64BC-4415-8C36-45A3B1AFB4A0Q29417124-84C8B491-69BD-4009-988D-0CF91689FAA9Q30054715-408F0EB4-31AA-480B-962E-15D7EFD959D2Q30657855-98EC8AE2-4F51-4A81-A49A-5C0EAC8F0004Q30945619-59EE6561-CCBA-44FF-B150-77C957E89588Q30984504-9010F549-DBE7-4C4E-B851-C5469C562BFAQ31160841-52FC9C29-66A0-4D9A-9CAD-897604FAA864Q33252484-4F4EA491-829D-45D4-89B3-5340F5584DC0Q33261882-F0FF6394-D399-41EE-9179-64A5735476CBQ33409853-8FD61D6B-57A8-4C29-BB2E-0F1D47E0EBE6Q33444591-7D257931-D3D7-4829-AB8A-9833922C1C8DQ33507084-F2E8EE4B-E34D-4943-85A3-5C881153145FQ33632430-7D733EC7-0D7E-4568-9529-A3AF449A62DBQ34023277-B358BCE3-55B1-4607-878A-1AA3B42E8091Q34108445-5F1444A9-288D-4650-B7C0-DFBB5B4555E9Q34145454-939606C7-D7CF-4744-AC7B-D264894C479EQ34156631-58540F50-6DEB-4E72-92FD-CB2F4A8E9C62Q34185576-9E6A1F27-30F1-480E-A5A0-DF52BFE6FCFEQ34255362-BE559068-1941-4761-A680-821A9B302B02
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Paul Rutgeerts
@ast
Paul Rutgeerts
@en
Paul Rutgeerts
@es
Paul Rutgeerts
@nl
Paul Rutgeerts
@sl
type
label
Paul Rutgeerts
@ast
Paul Rutgeerts
@en
Paul Rutgeerts
@es
Paul Rutgeerts
@nl
Paul Rutgeerts
@sl
prefLabel
Paul Rutgeerts
@ast
Paul Rutgeerts
@en
Paul Rutgeerts
@es
Paul Rutgeerts
@nl
Paul Rutgeerts
@sl
P1006
P214
P244
P1006
P106
P21
P213
0000 0003 8566 4449
P214
P244
P31
P735
P7859
lccn-n87843008